GlassScriptPhysician profile
Hanna Saba
NPI 1720070386
$7,983.06
in general payments reported to CMS, 2019-2025
60 companies · $837 in 2025
The $837 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,196 · 2020: $339 · 2021: $829 · 2022: $1,509 · 2023: $938 · 2024: $1,335 · 2025: $837.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,981 · Education: $130.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,980.60 |
| Education | $129.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $750.05 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $586.29 | 2019-2025 | Keytruda, Lynparza |
| E.R. Squibb & Sons, L.L.C. | $511.75 | 2019-2025 | Opdivo, Opdualag |
| Astrazeneca Pharmaceuticals LP | $440.81 | 2019-2025 | Lynparza, Calquence, Imfinzi |
| Genentech USA, INC. | $423.16 | 2019-2022 | |
| Pfizer INC. | $419.93 | 2019-2025 | |
| Astellas Pharma US INC | $387.32 | 2019-2025 | Xtandi, Xospata, Padcev |
| Janssen Biotech, INC. | $367.88 | 2019-2025 | Erleada, Talvey, Darzalex |
| Celgene Corporation | $313.24 | 2019-2025 | Reblozyl |
| Genzyme Corporation | $294.89 | 2019-2024 | |
| Rigel Pharmaceuticals, INC. | $245.26 | 2019-2025 | Rezlidhia, Tavalisse, Gavreto |
| Abbvie INC. | $239.20 | 2019-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $224.43 | 2019-2022 | |
| Beigene USA, INC. | $209.40 | 2020-2024 | Brukinsa |
| Amgen INC. | $188.21 | 2019-2023 | Blincyto, Kyprolis |
Show all 60 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hanna Saba listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.